Monday, September 25, 2023 12:24:04 PM
Question motives.
Establish and rely upon fall-back positions.
Sidetrack opponents with name calling and ridicule. (MicTrade just jumped in with this tactic)
Hear no evil, see no evil, speak no evil.
Change the subject.
Emotionalize, Antagonize, and Goad Opponents.
Proper response: Be a champion of the truth without becoming drawn into overly passionate discourse and losing your cool.
https://www.ethosdebate.com/lies-rhetoric-4-18-rules-disinformation/
Fall back position being being your main goto. I present evidence and as you usually do, you turn the convo back to Sonny ignoring evidence presented. Then when you do attack the CEO, you fail to present any actual evidence of corruption or even that he is ruining the company in any fashion. I'd say from a commercialization perspective hes seemingly done little (Although i seem him lining up products for a reason) but from an R&D perspective hes been pretty successful. R&D being his strength considering hes been doing it for 20 years.
You have evidence that he has doing nothing to protect investors. Although warrants do have price change mechanisms to protect those that purchase offerings which is the least risky (least risky doesnt mean absent of risk) way to purchase shares. Still you have to own a few shares to get access to the poison pill shareholder rights offerings. This is another reason to own 10-100 shares as there is a good chance of another shareholder rights offering coming before the annual vote this year.
To correct myself, i said this study was published in 2018, but it wasnt submitted until June 2019 and published December 2019. It was likely this study was in the works when Zimmer Biomet hired Dr. Lal.
https://www.researchgate.net/profile/Saurabh-Lal
https://www.sciencedirect.com/science/article/abs/pii/S1751616119309099
Xfund being just another incarnation of Entlarvt as well as CS101. Same person different aliases.
Establish and rely upon fall-back positions.
Sidetrack opponents with name calling and ridicule. (MicTrade just jumped in with this tactic)
Hear no evil, see no evil, speak no evil.
Change the subject.
Emotionalize, Antagonize, and Goad Opponents.
Proper response: Be a champion of the truth without becoming drawn into overly passionate discourse and losing your cool.
https://www.ethosdebate.com/lies-rhetoric-4-18-rules-disinformation/
Fall back position being being your main goto. I present evidence and as you usually do, you turn the convo back to Sonny ignoring evidence presented. Then when you do attack the CEO, you fail to present any actual evidence of corruption or even that he is ruining the company in any fashion. I'd say from a commercialization perspective hes seemingly done little (Although i seem him lining up products for a reason) but from an R&D perspective hes been pretty successful. R&D being his strength considering hes been doing it for 20 years.
You have evidence that he has doing nothing to protect investors. Although warrants do have price change mechanisms to protect those that purchase offerings which is the least risky (least risky doesnt mean absent of risk) way to purchase shares. Still you have to own a few shares to get access to the poison pill shareholder rights offerings. This is another reason to own 10-100 shares as there is a good chance of another shareholder rights offering coming before the annual vote this year.
To correct myself, i said this study was published in 2018, but it wasnt submitted until June 2019 and published December 2019. It was likely this study was in the works when Zimmer Biomet hired Dr. Lal.
https://www.researchgate.net/profile/Saurabh-Lal
https://www.sciencedirect.com/science/article/abs/pii/S1751616119309099
Xfund being just another incarnation of Entlarvt as well as CS101. Same person different aliases.
Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?
Recent SINT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 12:30:10 PM
- SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution • GlobeNewswire Inc. • 03/23/2026 01:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 09:00:53 PM
- SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 01:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 01:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:00:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:35:38 PM
- SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms • GlobeNewswire Inc. • 02/18/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:45:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:44:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:43:48 AM
- SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 • GlobeNewswire Inc. • 01/29/2026 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/12/2025 05:15:20 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/09/2025 10:01:07 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 01:00:05 PM
- SINTX Technologies to Participate in Sidoti & Company Investor Conference • GlobeNewswire Inc. • 12/08/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 01:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:35:26 PM
- SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants • GlobeNewswire Inc. • 12/01/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 01:05:43 PM
